San Antonio Military Medical Center, San Antonio, Texas.
Ann Allergy Asthma Immunol. 2013 Dec;111(6):562-6. doi: 10.1016/j.anai.2013.08.021. Epub 2013 Sep 18.
Rush immunotherapy (RIT) schedules can expedite protection in individuals sensitive to imported fire ant (IFA) stings.
To evaluate the safety and efficacy of 1-day RIT with IFA whole body extract (WBE) and determine the benefit of premedication with antihistamines and prednisone.
Patients with systemic reactions to IFAs and evidence of specific IgE by skin test or serologic test started a 1-day RIT protocol without premedication. The 1-day RIT protocol consisted of a total of 10 injections every 30 to 60 minutes to achieve a 0.3-mL 1:100 (wt/vol) dose. A higher systemic reaction rate (SRR) prompted protocol revision to include a 3-day course of oral 20 mg of prednisone twice daily, 150 mg of ranitidine, and 10 mg of loratadine started 2 days before the 1-day RIT. Patients returned on days 8 and 15 to receive a 0.5 mL 1:100 (wt/vol) maintenance injection. The effectiveness of the RIT was evaluated with a sting challenge on approximately day 22.
Eighty of the 96 patients enrolled initiated the 1-day RIT. The first nonpremedicated group exhibited a SRR of 24.3% (9 of 37 patients), whereas the revised premedicated group had a SRR of 9.5% (4 of 42 patients; P = .07). The most severe reaction during RIT included dizziness, angioedema, and urticaria. Sting challenges on 53 patients resulted in 1 mild rhinitis reaction (efficacy, 98.1%).
One-day RIT with IFA WBE for IFA hypersensitivity is efficacious. Although there was a trend with premedications to reduce SRRs during the RIT, safety data with premedication require confirmation in a larger trial.
速发型免疫疗法(RIT)方案可以加快对进口火蚁(IFA)蜇伤敏感个体的保护。
评估 IFA 全身提取物(WBE)1 天 RIT 的安全性和有效性,并确定抗组胺药和泼尼松预用药的益处。
对 IFA 有全身性反应且皮肤试验或血清学试验有特异性 IgE 证据的患者开始进行 1 天 RIT 方案,无需预用药。1 天 RIT 方案包括总共 10 次注射,每 30 至 60 分钟一次,以达到 0.3 毫升 1:100(重量/体积)剂量。较高的全身性反应率(SRR)促使方案修订,包括在 1 天 RIT 前 2 天开始为期 3 天的每日 2 次口服 20 毫克泼尼松、150 毫克雷尼替丁和 10 毫克氯雷他定。患者在第 8 天和第 15 天返回接受 0.5 毫升 1:100(重量/体积)维持注射。大约在第 22 天进行蜇刺挑战来评估 RIT 的有效性。
96 名入组患者中有 80 名开始了 1 天 RIT。第一个未预用药组的 SRR 为 24.3%(37 名患者中的 9 名),而修订后的预用药组的 SRR 为 9.5%(42 名患者中的 4 名;P=0.07)。RIT 期间最严重的反应包括头晕、血管性水肿和荨麻疹。对 53 名患者进行的蜇刺挑战导致 1 例轻度鼻炎反应(疗效为 98.1%)。
IFA 全身提取物(WBE)用于 IFA 过敏的 1 天 RIT 是有效的。虽然预用药有降低 RIT 期间 SRR 的趋势,但预用药的安全性数据需要在更大的试验中确认。